amantadine has been researched along with Hepatitis C in 30 studies
amant: an antiviral compound consisting of an adamantane derivative chemically linked to a water-solube polyanioic matrix; structure in first source
Hepatitis C: INFLAMMATION of the LIVER in humans caused by HEPATITIS C VIRUS, a single-stranded RNA virus. Its incubation period is 30-90 days. Hepatitis C is transmitted primarily by contaminated blood parenterally and is often associated with transfusion and intravenous drug abuse. However, in a significant number of cases, the source of hepatitis C infection is unknown.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine whether addition of amantadine to pegylated interferon/ribavirin improved response rates among chronic hepatitis C patients, non-responders to interferon/ribavirin and study the dynamic of response." | 9.12 | Amantadine triple therapy for non-responder hepatitis C patients. Clues for controversies (ANRS HC 03 BITRI). ( Adeleine, P; Bailly, F; Maynard, M; Nemoz, C; Pradat, P; Rozier, F; Si Ahmed, SN; Trépo, C, 2006) |
| "Our results show that triple antiviral therapy for 48 weeks induced a sustained virological response in 33% of IFN-ribavirin nonresponders with recurrent hepatitis C." | 9.11 | Triple antiviral therapy with amantadine for IFN-ribavirin nonresponders with recurrent posttransplantation hepatitis C. ( Adham, M; Baulieux, J; Bizollon, T; Chevallier, M; Ducerf, C; Pradat, P; Trepo, C; Zoulim, F, 2005) |
| "To evaluate the efficacy and safety of combination therapy with interferon-alpha2b (3 MU, 3 times weekly), ribavirin (600 mg daily) and amantadine (100 mg daily) in post-transplant hepatitis C." | 7.71 | Interferon-alpha plus ribavirin and amantadine in patients with post-transplant hepatitis C: results of a pilot study. ( Andreone, P; Bernardi, M; Biselli, M; Cavallari, A; Cursaro, C; D'Errico, A; Di Giammarino, L; Galli, S; Gramenzi, A; Grazi, GL; Jovine, E; Mazziotti, A, 2001) |
| " Its combination with pegylated interferon and ribavirin needs further evaluation." | 6.77 | Randomized controlled trial of interferon gamma versus amantadine in combination with interferon alpha and ribavirin for hepatitis C genotype 3 non-responders and relapsers. ( Abbas, Z; Hamid, S; Jafri, W; Raza, S, 2012) |
| "Amantadine was given orally (200 mg/d) for 3 months." | 5.33 | Amantadine monotherapy is ineffective in the treatment of hepatitis C virus recurrence in the post-liver transplantation setting. ( Angelico, M; Anselmo, A; D'Andria, D; de Liguori Carino, N; de'Liguori Carino, N; Ielpo, B; Manzia, T; Muzi, F; Orlando, G; Sabato Ceraldi, S; Tariciotti, L; Tisone, G, 2005) |
| "To determine whether addition of amantadine to pegylated interferon/ribavirin improved response rates among chronic hepatitis C patients, non-responders to interferon/ribavirin and study the dynamic of response." | 5.12 | Amantadine triple therapy for non-responder hepatitis C patients. Clues for controversies (ANRS HC 03 BITRI). ( Adeleine, P; Bailly, F; Maynard, M; Nemoz, C; Pradat, P; Rozier, F; Si Ahmed, SN; Trépo, C, 2006) |
| "Our results show that triple antiviral therapy for 48 weeks induced a sustained virological response in 33% of IFN-ribavirin nonresponders with recurrent hepatitis C." | 5.11 | Triple antiviral therapy with amantadine for IFN-ribavirin nonresponders with recurrent posttransplantation hepatitis C. ( Adham, M; Baulieux, J; Bizollon, T; Chevallier, M; Ducerf, C; Pradat, P; Trepo, C; Zoulim, F, 2005) |
| "Twenty consecutive adult patients with chronic hepatitis C who had failed to respond to a 6-month course of interferon alpha were randomly assigned to receive a combination of interferon alpha + oral ribavirin (double therapy), or the same combination + oral amantadine (triple therapy), for 6 months." | 5.09 | Pilot study of triple antiviral therapy for chronic hepatitis C in interferon alpha non-responders. ( Bolondi, L; Brillanti, S; Di Tomaso, M; Foli, M; Gramantieri, L; Masci, C, 1999) |
| " Combination therapy with Interferon-α and ribavirin remains the backbone treatment for chronic hepatitis C; the addition of serine protease inhibitors improves the treatment outcome of patients infected with hepatitis C virus genotype 1." | 4.87 | Antiviral drugs for viruses other than human immunodeficiency virus. ( Razonable, RR, 2011) |
| "Acute and chronic hepatitis C virus (HCV) infection remains a serious health problem worldwide, however, there has been advancement in the treatment of HCV infection due to standard treatment using pegylated interferon and ribavirin." | 4.84 | Treatment of hepatitis C virus infection. ( Encke, J; Stremmel, W; Weigand, K, 2007) |
| " At present the recommended treatment for patients with chronic hepatitis C is a combination of pegylated interferon and ribavirin." | 4.82 | [Current treatment of hepatitis C virus infection]. ( Avci, A; Erhardt, A; Häussinger, D; Heintges, T; Lörke, J, 2005) |
| "To evaluate the efficacy and safety of combination therapy with interferon-alpha2b (3 MU, 3 times weekly), ribavirin (600 mg daily) and amantadine (100 mg daily) in post-transplant hepatitis C." | 3.71 | Interferon-alpha plus ribavirin and amantadine in patients with post-transplant hepatitis C: results of a pilot study. ( Andreone, P; Bernardi, M; Biselli, M; Cavallari, A; Cursaro, C; D'Errico, A; Di Giammarino, L; Galli, S; Gramenzi, A; Grazi, GL; Jovine, E; Mazziotti, A, 2001) |
| "At present the treatment of hepatitis C virus infection (HCV) has improved because of combined treatment with interferon (IFN) and ribavirin." | 3.71 | Hepatitis C: who should you treat and how? ( Rodés, J; Sánchez Tapias, JM, 2002) |
| " Its combination with pegylated interferon and ribavirin needs further evaluation." | 2.77 | Randomized controlled trial of interferon gamma versus amantadine in combination with interferon alpha and ribavirin for hepatitis C genotype 3 non-responders and relapsers. ( Abbas, Z; Hamid, S; Jafri, W; Raza, S, 2012) |
| "Antiviral therapy to treat recurrent hepatitis C infection after liver transplantation is controversial due to unresolved balance between benefits and harms." | 2.46 | Antiviral therapy for recurrent liver graft infection with hepatitis C virus. ( Burroughs, AK; Davidson, BR; Gurusamy, KS; Tsochatzis, E; Xirouchakis, E, 2010) |
| "Amantadine was given orally (200 mg/d) for 3 months." | 1.33 | Amantadine monotherapy is ineffective in the treatment of hepatitis C virus recurrence in the post-liver transplantation setting. ( Angelico, M; Anselmo, A; D'Andria, D; de Liguori Carino, N; de'Liguori Carino, N; Ielpo, B; Manzia, T; Muzi, F; Orlando, G; Sabato Ceraldi, S; Tariciotti, L; Tisone, G, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (6.67) | 18.2507 |
| 2000's | 21 (70.00) | 29.6817 |
| 2010's | 7 (23.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benschop, KS | 1 |
| van der Avoort, HG | 1 |
| Duizer, E | 1 |
| Koopmans, MP | 1 |
| Nair, S | 1 |
| Lipscomb, J | 1 |
| Eason, J | 1 |
| Griffin, S | 3 |
| Stgelais, C | 1 |
| Owsianka, AM | 1 |
| Patel, AH | 1 |
| Rowlands, D | 2 |
| Harris, M | 3 |
| Gurusamy, KS | 1 |
| Tsochatzis, E | 1 |
| Xirouchakis, E | 1 |
| Burroughs, AK | 1 |
| Davidson, BR | 1 |
| Wozniak, AL | 2 |
| Yi, M | 1 |
| Lemon, SM | 1 |
| Weinman, SA | 2 |
| Foster, TL | 1 |
| Verow, M | 1 |
| Bentham, MJ | 1 |
| Thompson, J | 1 |
| Atkins, E | 1 |
| Fishwick, C | 1 |
| Foster, R | 1 |
| Razonable, RR | 1 |
| Abbas, Z | 1 |
| Raza, S | 1 |
| Hamid, S | 1 |
| Jafri, W | 1 |
| Chen, J | 1 |
| Shi, J | 1 |
| Xie, WF | 1 |
| Zeng, X | 1 |
| Lin, Y | 1 |
| Vrolijk, JM | 1 |
| de Knegt, RJ | 1 |
| Veldt, BJ | 1 |
| Orlent, H | 1 |
| Schalm, SW | 1 |
| Bizollon, T | 1 |
| Adham, M | 1 |
| Pradat, P | 2 |
| Chevallier, M | 1 |
| Ducerf, C | 1 |
| Baulieux, J | 1 |
| Zoulim, F | 1 |
| Trepo, C | 2 |
| Muzi, F | 1 |
| Orlando, G | 1 |
| Ielpo, B | 1 |
| Anselmo, A | 1 |
| Sabato Ceraldi, S | 1 |
| de Liguori Carino, N | 1 |
| de'Liguori Carino, N | 1 |
| Manzia, T | 1 |
| D'Andria, D | 1 |
| Tariciotti, L | 1 |
| Angelico, M | 1 |
| Tisone, G | 1 |
| Romero Gómez, M | 1 |
| Lörke, J | 1 |
| Avci, A | 1 |
| Erhardt, A | 1 |
| Heintges, T | 1 |
| Häussinger, D | 1 |
| Maynard, M | 1 |
| Bailly, F | 1 |
| Rozier, F | 1 |
| Nemoz, C | 1 |
| Si Ahmed, SN | 1 |
| Adeleine, P | 1 |
| Zeuzem, S | 1 |
| Fargion, S | 1 |
| Borzio, M | 1 |
| Maraschi, A | 1 |
| Cargnel, A | 1 |
| Wohnsland, A | 1 |
| Hofmann, WP | 1 |
| Sarrazin, C | 1 |
| Weigand, K | 1 |
| Stremmel, W | 1 |
| Encke, J | 1 |
| Wenger, C | 1 |
| Bischof, T | 1 |
| Gonvers, JJ | 1 |
| Renner, EL | 1 |
| Mullhaupt, B | 1 |
| Smith, JP | 1 |
| Brillanti, S | 1 |
| Foli, M | 1 |
| Di Tomaso, M | 1 |
| Gramantieri, L | 1 |
| Masci, C | 1 |
| Bolondi, L | 1 |
| Pianko, S | 1 |
| McHutchison, J | 1 |
| Wright, M | 1 |
| Main, J | 1 |
| Thomas, HC | 1 |
| Pol, S | 1 |
| Fontaine, H | 1 |
| Vallet-Pichard, A | 1 |
| Boyle, BA | 1 |
| Sax, H | 1 |
| Friedl, A | 1 |
| Renner, E | 1 |
| Steuerwald, MH | 1 |
| Weber, R | 1 |
| Andreone, P | 1 |
| Gramenzi, A | 1 |
| Cursaro, C | 1 |
| Biselli, M | 1 |
| Di Giammarino, L | 1 |
| Grazi, GL | 1 |
| Jovine, E | 1 |
| D'Errico, A | 1 |
| Galli, S | 1 |
| Mazziotti, A | 1 |
| Cavallari, A | 1 |
| Bernardi, M | 1 |
| Sánchez Tapias, JM | 1 |
| Rodés, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Interferon-gamma With Interferon Alpha and Ribavirin for Hepatitis C Patients Who Are Non-responders to Interferon Alpha Plus Ribavirin[NCT00538811] | Phase 2/Phase 3 | 40 participants (Anticipated) | Interventional | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
11 reviews available for amantadine and Hepatitis C
| Article | Year |
|---|---|
Antivirals against enteroviruses: a critical review from a public-health perspective.
Topics: Amantadine; Antiviral Agents; Child; Clinical Trials as Topic; Coinfection; Drug Resistance, Viral; | 2015 |
Antiviral therapy for recurrent liver graft infection with hepatitis C virus.
Topics: Amantadine; Antiviral Agents; Hepacivirus; Hepatitis C; Humans; Interferons; Liver Transplantation; | 2010 |
Antiviral drugs for viruses other than human immunodeficiency virus.
Topics: Acyclovir; Adenine; Amantadine; Antiviral Agents; Comorbidity; Drug Therapy, Combination; Foscarnet; | 2011 |
Meta-analysis: amantadine may lower the efficacy of pegylated interferon plus ribavirin in treatment-naive hepatitis C genotype 1 patients.
Topics: Amantadine; Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Interfero | 2012 |
Consensus conference. Treatment of hepatitis C.
Topics: Adult; Aged; Alcoholism; Amantadine; Antiviral Agents; Body Weight; Child; Drug Therapy, Combination | 2002 |
The treatment of hepatitis C: history, presence and future.
Topics: Amantadine; Antiviral Agents; Chronic Disease; Consensus; Drug Therapy, Combination; Hepatitis C; Hu | 2004 |
[Current treatment of hepatitis C virus infection].
Topics: Acute Disease; Amantadine; Animals; Antiviral Agents; Hepacivirus; Hepatitis B; Hepatitis C; Hepatit | 2005 |
Viral determinants of resistance to treatment in patients with hepatitis C.
Topics: Amantadine; Antiviral Agents; Drug Resistance, Viral; Hepacivirus; Hepatitis C; Humans; Interferon-a | 2007 |
Treatment of hepatitis C virus infection.
Topics: Acute Disease; Amantadine; Antiviral Agents; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon a | 2007 |
Drug-resistant viral hepatitis.
Topics: Amantadine; Antiviral Agents; Drug Resistance, Microbial; Hepacivirus; Hepatitis B; Hepatitis B e An | 2000 |
[Treatments for hepatitis virus C infections].
Topics: Amantadine; Antiviral Agents; Carcinoma, Hepatocellular; Hepatitis C; Humans; Interferon-alpha; Live | 2001 |
9 trials available for amantadine and Hepatitis C
| Article | Year |
|---|---|
Efficacy of interferon based antiviral therapy for recurrent hepatitis C in patients who received steroid free immunosuppression for liver transplantation.
Topics: Amantadine; Antibodies, Monoclonal; Antilymphocyte Serum; Antiviral Agents; Disease Progression; Dru | 2008 |
Randomized controlled trial of interferon gamma versus amantadine in combination with interferon alpha and ribavirin for hepatitis C genotype 3 non-responders and relapsers.
Topics: Adult; Amantadine; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C; Humans; Interfe | 2012 |
Triple antiviral therapy with amantadine for IFN-ribavirin nonresponders with recurrent posttransplantation hepatitis C.
Topics: Adult; Amantadine; Antiviral Agents; Blood Cell Count; Drug Therapy, Combination; Female; Hepaciviru | 2005 |
Amantadine triple therapy for non-responder hepatitis C patients. Clues for controversies (ANRS HC 03 BITRI).
Topics: Adult; Aged; Amantadine; Antiviral Agents; Biopsy; Double-Blind Method; Drug Therapy, Combination; F | 2006 |
Triple antiviral therapy in HCV positive patients who failed prior combination therapy.
Topics: Adolescent; Adult; Aged; Amantadine; Antiviral Agents; Biopsy; Drug Therapy, Combination; Female; He | 2006 |
Interferon and ribavirin with or without amantadine for interferon non-responders with chronic hepatitis C. A randomized, controlled pilot study.
Topics: Adolescent; Adult; Aged; Amantadine; Chronic Disease; Drug Therapy, Combination; Female; Hepatitis C | 2007 |
Treatment of chronic hepatitis C with amantadine.
Topics: Adolescent; Aged; Alanine Transaminase; Amantadine; Antiviral Agents; Chronic Disease; Female; Hepac | 1997 |
Pilot study of triple antiviral therapy for chronic hepatitis C in interferon alpha non-responders.
Topics: Adult; Alanine Transaminase; Amantadine; Antiviral Agents; Drug Therapy, Combination; Female; Hepati | 1999 |
Pilot study of interferon-alpha with and without amantadine for the treatment of hepatitis C in HIV coinfected individuals on antiretroviral therapy.
Topics: Adult; Amantadine; Antiviral Agents; CD4 Lymphocyte Count; Drug Interactions; Female; Hepatitis C; H | 2001 |
10 other studies available for amantadine and Hepatitis C
| Article | Year |
|---|---|
Genotype-dependent sensitivity of hepatitis C virus to inhibitors of the p7 ion channel.
Topics: 1-Deoxynojirimycin; Amantadine; Amino Acid Sequence; Antiviral Agents; Carcinoma, Hepatocellular; Ce | 2008 |
Intracellular proton conductance of the hepatitis C virus p7 protein and its contribution to infectious virus production.
Topics: Amantadine; Antifungal Agents; Antiviral Agents; Blotting, Western; Electroporation; Hepacivirus; He | 2010 |
Resistance mutations define specific antiviral effects for inhibitors of the hepatitis C virus p7 ion channel.
Topics: Amantadine; Amino Acid Sequence; Antiviral Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug | 2011 |
Amantadine monotherapy is ineffective in the treatment of hepatitis C virus recurrence in the post-liver transplantation setting.
Topics: Amantadine; Antiviral Agents; Azathioprine; Cyclosporine; Female; Hepatitis C; Humans; Immunosuppres | 2005 |
Hepatitis C: are there any options for non-responders?
Topics: Amantadine; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; | 2005 |
The American Association For the Study of Liver Diseases: new perspectives in the treatment of hepatitis C.
Topics: Amantadine; Antiviral Agents; Hepacivirus; Hepatitis C; Humans; Interferons; Mutation; Patient Compl | 2006 |
Retreatment of hepatitis C patients who do not respond to interferon: the search continues.
Topics: Amantadine; Antiviral Agents; Drug Therapy, Combination; Hepatitis C; Humans; Interferon-alpha; Riba | 2000 |
Recent advances in the management and treatment of GI and hepatic diseases associated with HIV: Part 2.
Topics: Amantadine; Antiviral Agents; Hepatitis B; Hepatitis C; HIV; HIV Infections; Humans; Interferon-alph | 2001 |
Interferon-alpha plus ribavirin and amantadine in patients with post-transplant hepatitis C: results of a pilot study.
Topics: Aged; Amantadine; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C; Humans; Interfer | 2001 |
Hepatitis C: who should you treat and how?
Topics: Amantadine; Antiviral Agents; Decision Making; Decision Trees; Drug Therapy, Combination; Hepatitis | 2002 |